Wedbush Lowers Earnings Estimates for Larimar Therapeutics
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Free Report) – Investment analysts at Wedbush reduced their Q1 2025 earnings per share (EPS) estimates for Larimar Therapeutics in a report released on Monday, March 24th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.39) per share for the quarter, down from their previous forecast of […]
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Free Report) – Investment analysts at Wedbush reduced their Q1 2025 earnings per share (EPS) estimates for Larimar Therapeutics in a report released on Monday, March 24th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.39) per share for the quarter, down from their previous forecast of […]
